Aquestive Says FDA Accepts Anaphylm NDA Resubmission For The Treatment Of Type I Allergic Reactions
Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a treatment for Type I allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The resubmission follows positive study results addressing prior FDA concerns. If approved, Anaphylm would be the first oral rescue medication for severe allergic reactions.
How this was made
The 30-second read
Why it matters
The FDA's Class 2 response and PDUFA date provide a clear timeline, reducing regulatory uncertainty and potentially attracting new capital.
Market read
Regulatory progress for a novel oral anaphylaxis treatment could move AQST shares and influence related biotech valuations.
What to watch
Potential competition from injectable epinephrine products and reimbursement uncertainties.
Background
Aquestive Therapeutics is a Nasdaq‑listed biotech developing Anaphylm, a sublingual film for severe allergic reactions.
Ticker impact
FDA accepted the NDA resubmission for Anaphylm, setting a PDUFA target of March 16, 2027.
potential upside as investors price in a likely approval if trials remain successful
Regulatory acceptance is a material catalyst for a micro‑cap biotech; market typically reacts positively to forward‑looking FDA milestones.
Market effects
May boost sentiment for allergy‑treatment and oral‑delivery biotech peers.
U.S. biotech sector could see modest lift in small‑cap indices.
Limited to investors tracking FDA pipeline developments.
Counterpoint
If clinical data later reveal safety concerns, the FDA acceptance may not translate into price gains.
Key entities
- companyAquestive Therapeutics, Inc.
Biopharmaceutical developer of Anaphylm.
- regulatorU.S. Food and Drug Administration
Agency that accepted the NDA resubmission.
